• Print
  • Send to a friend
  • Comment (0)
  •  

Canadian 'Frankenfish' moves closer to FDA approval for human consumption

Published on January 4, 2013
Published on January 4, 2013
Topics :
U.S. FDA , U.S. Food and Drug Administration , University of Toronto , Canada , Prince Edward Island , Panama

Genetically engineered salmon created in Canada are getting closer to becoming the first transgenic animal to be approved for human consumption after the U.S. Food and Drug Administration found the fish have no significant environmental impact.

The FDA published its draft environmental assessment last month — one of the final steps in what has been a 17-year regulatory process.

The AquAdvantage salmon developed at Memorial University and the University of Toronto consists of an Atlantic salmon egg that includes genes from Chinook salmon and an eel-like fish called the ocean pout.

AquaBounty Technologies is the Massachussetts-based company that produces the GM salmon eggs at a farm in Prince Edward Island and rears the fish at a fish farm in Panama.

The company says the modification means the salmon grow twice as fast as conventional fish.

Critics fear the so-called Frankenfish could escape their inland fish farms and affect wild populations, and they tried unsuccessfully to have Congress derail the FDA process.

The U.S. FDA has already found the AquAdvantage salmon are safe to eat.

© Canadian Press

Submit a comment

Submit a comment (we keep all emails private)
Agreement

We ask that users remain courteous. You may not post insulting, discriminatory or inappropriate content, which may be removed at our discretion. We are not responsible for user content and opinions. Use of this site as well as content submission & ownership are governed by our Conditions of Use and Privacy Policy.

Member organizations should be non-profit in nature, and promote legal activities. Any organization found promoting illegal activities or commercial products or services will be deleted from the site.

I agree with these conditions.

Advertising

Newsletter

Please enter your email to receive our free newsletter

Subscribe to news alerts

Advertising